Form 8-K Summary
Registrant: Coeptis Therapeutics Holdings, Inc. (the provided metadata identifies “Z Squared Inc.,” which does not match the filing)
Report date: August 28, 2023; filed August 30, 2023
Business Context and Reporting Period
The filing reports a Nasdaq continued-listing deficiency under Item 3.01. Coeptis Therapeutics Holdings, Inc. is listed on the Nasdaq Capital Market under the symbols COEP (common stock) and COEPW (warrants).
Key Financial and Liquidity Information
The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Change and Listing Status
- Nasdaq notified the company that its Market Value of Listed Securities (MVLS) had remained below the $35 million minimum required for continued listing under Nasdaq Listing Rule 5550(b)(2) for 33 consecutive business days.
- The deficiency letter had no immediate effect on the listing or trading of the company’s securities.
- The company received an initial 180-calendar-day compliance period, ending February 26, 2024.
- To regain compliance, MVLS must close at or above $35 million for at least 10 consecutive business days before the deadline, subject to Nasdaq’s discretion.
Outlook, Risks, and Contingencies
- If compliance is not restored by February 26, 2024, Nasdaq is expected to notify the company that its securities are subject to delisting.
- The company may appeal a delisting determination to a Nasdaq hearings panel.
- Management stated it will monitor MVLS and evaluate options, including seeking an extension, appealing to a Nasdaq hearings panel, or pursuing an alternative listing.
- The principal identified risk is potential delisting if the company cannot restore the required market value within the applicable period.
Important Facts for Investors to Verify
- Whether the company restored MVLS compliance before February 26, 2024, and whether Nasdaq granted any extension.
- Any subsequent Nasdaq delisting notice, appeal, hearing decision, or alternative-listing action.
- The company’s current market value, share price, capitalization structure, and potential dilution affecting MVLS.
- The identity of the registrant, since the filing names Coeptis Therapeutics Holdings, Inc., not Z Squared Inc.